Summit Therapeutics Share Discussion Threads

[chrisatrdg] 20/6/2016 16:08

Per Free-Money from the other Board this afternoon:

'target is $26, representing up 221%

Analysts are bullish :



Just Analysts notes and we're probably set to go well beyond that if they announce the Ridi deal as expected with one or more Pharma's. GLA'

[hugus maximus] 20/6/2016 15:44

Great stuff! So good news for the micro biome. Are we to assume there's no specific data to come about specific strains of virulent C Diff? I'm surprised that theres no RNS about the above as surely this info could be share price sensitive info?

[waterloo01] 20/6/2016 14:29

Treatment with ridinilazole resulted in no significant decrease in these specific microbiota groups and total bacteria. Neither vancomycin nor ridinilazole resulted in any significant change in Enterobacteriaceae levels. Conclusions: These findings indicate that ridinilazole is superior to vancomycin in sparing these major components of the native microbiome during treatment of CDI, which may be responsible for the marked reduction in disease recurrence rates following ridinilazole therapy.

[chrisatrdg] 20/6/2016 13:46

The following poster has had its embargo lifted see below:

Session 393 - Monday Late-Breaker Poster Presentations
LB-116 / LB-116 - Ridinilazole Preserves Major Components of the Intestinal Microbiota During Treatment of Clostridium difficile Infection



Edit:bacterial groups found are named !!

[waterloo01] 20/6/2016 13:39

As they are presenting new data today at 4.30 (UK time), I suspect we will get an RNS at 4.30 and too late for then UK to trade.

[hugus maximus] 20/6/2016 12:52

Someuwin - agree completely. There are some PI's on NASDAQ message boards who have small holdings in SMMT but IMHO they will take little significant interest until either:

1. DMD P2 results start to show positive results .. even initial news. ( .. by which time the cash will have run out!)
2. Funding comes through a deal with C Diif.
3. A placement

So long as we run on empty, interest will be limited.

[someuwin] 20/6/2016 11:11

The big issue here smarm is the cash level. imo.

Will they get a deal for the C Diff drug before they need to raise funds again?


* Cash and cash equivalents at 30 April 2016 of GBP10.0 million compared to GBP16.3 million at 31 January 2016

* Loss for the three months ended 30 April 2016 of GBP5.2 million compared to a loss of GBP3.4 million for the three months ended 30 April 2015

[smarm] 20/6/2016 11:03

Someuwin, what do you think the timeline is here? Obviously all moving much slower than hoped but in your opinion are things now on the turn for better?

S

[waterloo01] 20/6/2016 07:43

I'll be in Italy unfortunately but trust others will ask the key questions.

[chrisatrdg] 19/6/2016 17:54

Hi waterloo01 - That is exactly what I am thinking maybe share price sensitive.

With regards the AGM are you able to go and for me I can make it this year and it should be interesting.

[waterloo01] 19/6/2016 16:27

Should be an RNS tomorrow with details of the latest on Rid'nazole from the poster presentation.

[someuwin] 17/6/2016 19:03

Summit Therapeutics ‏@Summitplc · 3 minutes ago

Meet our CMO Ralf Rosskamp @JettFoundation 's #Duchenne roundtable in Columbus, OH, tomorrow! He can answer any ?s about PhaseOut DMD

[chrisatrdg] 17/6/2016 16:16

AGM RNS out all documents on website - happy reading.

[luminoso] 17/6/2016 12:28

Agree, Hyper.

[luminoso] 17/6/2016 12:09

MM's have optimistically marked us up a penny on the news. No doubt cue for a raft of brexity sales ?

[luminoso] 17/6/2016 12:08

Beat me to it, waterloo.

[chrisatrdg] 17/6/2016 10:48

Presentation from this week now posted on Summit site.

[luminoso] 16/6/2016 23:42

" That's exactly what we were all saying 2.5 years ago."

No it wasn't, because the progress that has been made in the last 2 years had not happened yet.

[someuwin] 16/6/2016 14:40

Summit Therapeutics ‏@Summitplc · 1m

Summit Therapeutics Retweeted Discovery Channel UK

Co-founder Prof Kay Davies discusses her work in #Duchenne and #utrophin in #TheChallenge on @DiscoveryUK this Sun!

[lithological heterogeneities] 16/6/2016 13:12

No, am talking about mkt cap, not share price

01.10.13.....18.05p with 447,357,841 shares in issue = £80.75 mkt cap
04.03.14.....821,228,226 shares in issue after massive dilution
03.06.14.....1:20 share split
04.07.14.....41,061,412 shares in issue post share split
17.06.15.....105p with 61.47m shares in issue = mkt cap £64.5m

So that's a drop from a mkt cap of £80.75m to £64.5m in just 2.5 years.
SUMM has dropped 20% in mkt cap value in 2.5 years.

As for "the progress of both C.Diff and DMD drugs has been very impressive, despite some delays, and they are definitely going places in the near future."

That's exactly what we were all saying 2.5 years ago.

Good luck this time around.

[luminoso] 16/6/2016 12:57

If you are talking about the share price, fair point. However the progress of both C.Diff and DMD drugs has been very impressive, despite some delays, and they are definitely going places in the near future.
I think thats a rounder picture than your throw away comment.